Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.48 |
| ▸ | RAMP3 | O60896 | 14/20 | 0.46 |
| ▸ | CALCR | P30988 | 14/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508488 | 0.85 | APLNR (0.45) | NAA50RAMP3CALCRCAPN1APLNR | |
| SCHEMBL31542106 | 0.80 | RAMP3 (0.47) | NAA50RAMP3CALCRCAPN1APLNR | |
| SCHEMBL31542114 | 0.78 | CAPN1 (0.50) | NAA50RAMP3CALCRCAPN1 | |
| SCHEMBL31542115 | 0.78 | CAPN1 (0.51) | NAA50RAMP3CALCRCAPN1 | |
| SCHEMBL16508596 | 0.76 | RAMP3 (0.53) | RAMP3CALCRAPLNR | |
| SCHEMBL29388041 | 0.75 | NPY2R (0.49) | CALCR | |
| SCHEMBL32674582 | 0.74 | RAMP3 (0.53) | RAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL30608596 | 0.74 | CAPN1 (0.49) | NAA50RAMP3CALCRCAPN1NTSR1 | |
| SCHEMBL31542111 | 0.73 | CAPN1 (0.43) | RAMP3CALCRCAPN1 | |
| SCHEMBL30974089 | 0.73 | RAMP3 (0.49) | RAMP3CALCRNMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | CXCR5, CXCR1, CCR5 | NAA50 3183/4885RAMP3 981/4885CALCR 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.